Amy Bachrodt
CIK: 0002050422
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (29 total)
- Aug 11, 2026LYCA
Lycia Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
399.7K shares- - Apr 1, 2026MAZE
Maze Therapeutics, Inc.
Exercise(M)Direct2.5K shares at avg. $10.42$26K - Apr 1, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Direct300 shares at avg. $30.34$9K - Apr 1, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Direct2.2K shares at avg. $29.32$65K - Mar 2, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Direct1.3K shares at avg. $44.44$58K - Mar 2, 2026MAZE
Maze Therapeutics, Inc.
Exercise(M)Direct5K shares at avg. $10.42$52K - Mar 2, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Direct3.7K shares at avg. $45.47$168K - Mar 2, 2026MAZE
Maze Therapeutics, Inc.
Award(A)DirectRestricted Stock Units
16K shares- - Mar 2, 2026MAZE
Maze Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
32K shares- - Feb 2, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Direct736 shares at avg. $46.63$34K - Feb 2, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Direct200 shares at avg. $44.15$9K - Feb 2, 2026MAZE
Maze Therapeutics, Inc.
Exercise(M)Direct156 shares at avg. $10.42$2K - Feb 2, 2026MAZE
Maze Therapeutics, Inc.
Exercise(M)Direct4.8K shares at avg. $10.42$50K - Feb 2, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Direct4.1K shares at avg. $46.03$187K - Jan 22, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Direct5K shares at avg. $45.52$228K - Jan 22, 2026MAZE
Maze Therapeutics, Inc.
Exercise(M)Direct2.5K shares at avg. $10.42$26K - Jan 22, 2026MAZE
Maze Therapeutics, Inc.
Exercise(M)Direct2.5K shares at avg. $10.42$26K - Jan 2, 2026MAZE
Maze Therapeutics, Inc.
Exercise(M)Direct4.8K shares at avg. $10.42$50K - Jan 2, 2026MAZE
Maze Therapeutics, Inc.
Exercise(M)Direct204 shares at avg. $10.42$2K - Jan 2, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Direct2.4K shares at avg. $38.70$93K - Jan 2, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Direct2.6K shares at avg. $39.57$103K - Dec 30, 2025MAZE
Maze Therapeutics, Inc.
Exercise(M)Direct2.4K shares at avg. $10.42$25K - Dec 30, 2025MAZE
Maze Therapeutics, Inc.
Sale(S)Direct5K shares at avg. $40.08$200K - Dec 30, 2025MAZE
Maze Therapeutics, Inc.
Exercise(M)Direct2.6K shares at avg. $10.42$27K - Dec 29, 2025MAZE
Maze Therapeutics, Inc.
Exercise(M)Direct124 shares at avg. $10.42$1K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 11, 2026 |  LYCA Lycia Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 399,746 | - | - | Direct |
| Apr 1, 2026 |  MAZE Maze Therapeutics, Inc. | Exercise(M) | 2,500 | $10.42 | $26,050 | Direct |
| Apr 1, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 300 | $30.34 | $9,101 | Direct |
| Apr 1, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 2,200 | $29.32 | $64,510 | Direct |
| Mar 2, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 1,300 | $44.44 | $57,774 | Direct |
| Mar 2, 2026 | MAZE Maze Therapeutics, Inc. | Exercise(M) | 5,000 | $10.42 | $52,100 | Direct |
| Mar 2, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 3,700 | $45.47 | $168,237 | Direct |
| Mar 2, 2026 | MAZE Maze Therapeutics, Inc. | Award(A) Restricted Stock Units | 16,000 | - | - | Direct |
| Mar 2, 2026 | MAZE Maze Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 32,000 | - | - | Direct |
| Feb 2, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 736 | $46.63 | $34,321 | Direct |
| Feb 2, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 200 | $44.15 | $8,830 | Direct |
| Feb 2, 2026 | MAZE Maze Therapeutics, Inc. | Exercise(M) | 156 | $10.42 | $1,626 | Direct |
| Feb 2, 2026 | MAZE Maze Therapeutics, Inc. | Exercise(M) | 4,844 | $10.42 | $50,474 | Direct |
| Feb 2, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 4,064 | $46.03 | $187,068 | Direct |
| Jan 22, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 5,000 | $45.52 | $227,612 | Direct |
| Jan 22, 2026 | MAZE Maze Therapeutics, Inc. | Exercise(M) | 2,503 | $10.42 | $26,081 | Direct |
| Jan 22, 2026 | MAZE Maze Therapeutics, Inc. | Exercise(M) | 2,497 | $10.42 | $26,019 | Direct |
| Jan 2, 2026 | MAZE Maze Therapeutics, Inc. | Exercise(M) | 4,796 | $10.42 | $49,974 | Direct |
| Jan 2, 2026 | MAZE Maze Therapeutics, Inc. | Exercise(M) | 204 | $10.42 | $2,126 | Direct |
| Jan 2, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 2,405 | $38.70 | $93,072 | Direct |
| Jan 2, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 2,595 | $39.57 | $102,681 | Direct |
| Dec 30, 2025 | MAZE Maze Therapeutics, Inc. | Exercise(M) | 2,395 | $10.42 | $24,956 | Direct |
| Dec 30, 2025 | MAZE Maze Therapeutics, Inc. | Sale(S) | 5,000 | $40.08 | $200,407 | Direct |
| Dec 30, 2025 | MAZE Maze Therapeutics, Inc. | Exercise(M) | 2,605 | $10.42 | $27,144 | Direct |
| Dec 29, 2025 | MAZE Maze Therapeutics, Inc. | Exercise(M) | 124 | $10.42 | $1,292 | Direct |
1-25 of 29 transactions
About Bachrodt Amy
Bachrodt Amy (SEC CIK 0002050422) files insider reports with the SEC as Chief Financial Officer of Lycia Therapeutics, Inc. (LYCA) and SVP, Finance of Maze Therapeutics, Inc. (MAZE).
Signal8 holds 10 ownership filings by Bachrodt Amy (2 Form 3, 8 Form 4), filed between Jan 30, 2025 and Oct 26, 2026. Those filings report 29 transactions, from Sep 22, 2025 to Aug 11, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Bachrodt Amy's filings is in SOUTH SAN FRANCISCO, CA.
Recent filings by Bachrodt Amy
- Aug 11, 2026: Grant or award of LYCA derivative securities (Form 4, code A).
- Apr 1, 2026: Option exercise of MAZE shares (Form 4, code M).
- Apr 1, 2026: Open-market sales of MAZE shares (2 lines, Form 4, code S).
- Mar 2, 2026: Open-market sale of MAZE shares (Form 4, code S).
- Mar 2, 2026: Option exercise of MAZE shares (Form 4, code M).
Other insiders filing for Lycia Therapeutics, Inc. (LYCA)
- Venrock Healthcare Capital Partners III, L.P., 10% Owner
- Versant Ventures VII GP, L.P., 10% Owner
- Fischer Laurent, Director
- Henderson Jane, Director
- RIEFLIN WILLIAM JL, Director
- Touami Sofia, Chief Business Officer